Association Between Social Vulnerability and SARS-CoV-2 Seroprevalence in Specimens Collected From Commercial Laboratories, United States, September 2021–February 2022
Public Health Reports® · 2024
DOI: 10.1177/00333549231223140 ↗Kurz gefasst
Fachartikel in der Zeitschrift Public Health Reports®, 2024. Verfasst von Tina J Benoit und 9 weiteren Autor:innen. Beteiligte Einrichtung: COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, Social Vulnerability. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objective
We conducted a national US study of SARS-CoV-2 seroprevalence by Social Vulnerability Index (SVI) that included pediatric data and compared the Delta and Omicron periods during the COVID-19 pandemic. The objective of the current study was to assess the association between SVI and seroprevalence of infection-induced SARS-CoV-2 antibodies by period (Delta vs Omicron) and age group.
Methods
We used results of infection-induced SARS-CoV-2 antibody assays of clinical sera specimens (N = 406 469) from 50 US states from September 2021 through February 2022 to estimate seroprevalence overall and by county SVI tercile. Bivariate analyses and multilevel logistic regression models assessed the association of seropositivity with SVI and its themes by age group (0-17, ≥18 y) and period (Delta: September–November 2021; Omicron: December 2021–February 2022).
Results
Aggregate infection-induced SARS-CoV-2 antibody seroprevalence increased at all 3 SVI levels; it ranged from 25.8% to 33.5% in September 2021 and from 53.1% to 63.5% in February 2022. Of the 4 SVI themes, socioeconomic status had the strongest association with seroprevalence. During the Delta period, we found significantly more infections per reported case among people living in a county with high SVI (odds ratio [OR] = 2.76; 95% CI, 2.31-3.21) than in a county with low SVI (OR = 1.65; 95% CI, 1.33-1.97); we found no significant difference during the Omicron period. Otherwise, findings were consistent across subanalyses by age group and period.
Conclusions
Among both children and adults, and during both the Delta and Omicron periods, counties with high SVI had significantly higher SARS-CoV-2 antibody seroprevalence than counties with low SVI did. These disparities reinforce SVI’s value in identifying communities that need tailored prevention efforts during public health emergencies and resources to recover from their effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA.
- ICF Inc, Fairfax, VA, USA.
- Office of Capacity Development and Applied Prevention Science, Agency for Toxic Substances and Disease Registry, Atlanta, GA, USA.
ORCID-Profile: Tina J Benoit, Kristie E N Clarke
Zitieren
APA
Benoit, T. J., Kim, Y., Deng, Y., Li, Z., Harding, L., Wiegand, R., Deng, X., Jones, J. M., Ronaldo, I., & Clarke, K. E. N. (2024). Association Between Social Vulnerability and SARS-CoV-2 Seroprevalence in Specimens Collected From Commercial Laboratories, United States, September 2021–February 2022. Public Health Reports®. https://doi.org/10.1177/00333549231223140
Vancouver
Benoit TJ, Kim Y, Deng Y, Li Z, Harding L, Wiegand R, et al. Association Between Social Vulnerability and SARS-CoV-2 Seroprevalence in Specimens Collected From Commercial Laboratories, United States, September 2021–February 2022. Public Health Reports®. 2024. doi:10.1177/00333549231223140
BibTeX
@article{Benoit2024,
author = {Benoit, Tina J and Kim, Yun and Deng, Yangyang and Li, Zheng and Harding, Lee and Wiegand, Ryan and Deng, Xiaoyi and Jones, Jefferson M and Ronaldo, Iachan and Clarke, Kristie E N},
title = {Association Between Social Vulnerability and SARS-CoV-2 Seroprevalence in Specimens Collected From Commercial Laboratories, United States, September 2021–February 2022},
journal = {Public Health Reports®},
year = {2024},
doi = {10.1177/00333549231223140}
}
EUVIMED